Nazzani et al. cN0 penile cancer DSNB cohort
In cN0 penile cancer, can DSNB guide selective treatment of occult nodal disease while reducing morbidity?
What changes for patients?
After inverse-probability weighting, 5-year cancer-specific survival was 90% with DSNB-guided selective dissection vs 77% with observation, while 5-year inguinal relapse-free survival was 90% vs 73%. Because this is nonrandomized evidence, the absolute difference should not be interpreted as a causal NNT. The key benefit is more accurate staging with less morbidity than prophylactic radical ILND.
NNT: Not defensible as a causal NNT; observational evidence
Clavien grade 3 complications
NNH: Not applicable; severe complications were lower with DSNB
HR: Cancer death HR 0.29 after weighting
Retrospective cohort; treatment-selection bias possible
The cohort supports DSNB-guided staging and selective lymph-node dissection in cN0 penile SCC, while the observational design limits causal survival inference.
- Nazzani S, et al. J Urol. 2021;206:354–363.
- Primary publication / source